Summary: How can using iPSCs as starting materials help with transforming cell therapies into standard care? This infographic highlights the key features of iPSCs as starting materials, from donor consent through to commercial innovation.

Summary: Experts discuss formulation development and purification strategies to increase throughput, reduce operating costs and decrease...

Summary: In this panel discussion, Endpoints News publisher, Arsalan Arif convenes some of the field's top experts to discuss...

Summary: During this Q&A, we discuss the challenges of mRNA development and manufacturing, potential solutions and where the industry may go next with mRNA therapies.

Summary: In this executive summary, Catalent Biologics offers advice to pharma companies on three key areas of auto-injector device development.

Summary: During this talk, hear the latest data leveraging GPEx Lightning to generate highly stable, highly productive cell pools and discuss how the GPEx...

Summary: During this presentation, experts will discuss the latest challenges in biophysical characterization and will present solutions to overcome these challenges.

Summary: Catalent Biologics’ drug product operations in Europe can formulate, fill and finish sterile products into a vial, syringe, or cartridge injectable format for clinical and...

Summary: Learn factors that drive the emergence of complex, protein-based biologics, areas in which these molecules are experiencing the fastest growth, and challenges in their development and advancement to the clinic.

Summary: This will be Endpoints’ 2021 look at 11 of the most important up-and-coming private biotechs in the business, independently selected by company founder and editor John Carroll.